Copyright
©2010 Baishideng.
World J Gastroenterol. May 28, 2010; 16(20): 2526-2530
Published online May 28, 2010. doi: 10.3748/wjg.v16.i20.2526
Published online May 28, 2010. doi: 10.3748/wjg.v16.i20.2526
Table 2 Clinicopathological characteristics of 60 patients affected by gastric DLBCL
Clinicopathological characteristics | |
Age (yr) | |
Median | 58 |
Range | 19-76 |
Sex | |
Male | 42 |
Female | 28 |
Performance status | |
ECOG 0 | 0 (65%) (39/60) |
ECOG 1 | 1 (28.3%) (17/60) |
ECOG 2 | 2 (3.3%) (17/60) |
Primary gastric site | |
Body | 18.3% (11/60) |
Antrum | 46.6% (28/60) |
Fundus | 10% (6/60) |
Antrum-body | 25% (15/60) |
Metastatic sites | |
No | 23.3% (14/60) |
Node | 55% (33/60) |
Pulmonary | 18.3% (11/60) |
Bone | 0% (0/60) |
Liver | 1.6% (1/60) |
Spleen | 0% (0/60) |
Pleural effusion | 1.6% (1/60) |
Bio-humoral parameters | |
Lactate dehydrogenase (high level) | 85.0% (51/60) |
β2 microglobulin (high level) | 60% (36/60) |
Lugano staging system | |
I | 28.3% (17/60) |
II | 46.6% (28/60) |
III | 16.6% (10/60) |
IV | 8.3% (5/60) |
B symptoms | 15% (9/60) |
- Citation: Leopardo D, Lorenzo GD, Renzo AD, Federico P, Luponio S, Buonerba C, Matano E, Merola G, Imbimbo M, Montesarchio E, Rea A, Merola MC, Placido SD, Palmieri G. Efficacy of rituximab in gastric diffuse large B cell lymphoma patients. World J Gastroenterol 2010; 16(20): 2526-2530
- URL: https://www.wjgnet.com/1007-9327/full/v16/i20/2526.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i20.2526